Trial Profile
Eptifibatide Versus Abciximab in Primary PCI for Acute ST Elevation Myocardial Infarction.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Jun 2023
Price :
$35
*
At a glance
- Drugs Eptifibatide (Primary) ; Abciximab
- Indications Embolism and thrombosis; Myocardial infarction
- Focus Therapeutic Use
- Acronyms EVA-AMI
- Sponsors GlaxoSmithKline; GSK
- 21 Jun 2010 Actual end date (Dec 2007) added as reported by ClinicalTrials.gov.
- 27 Apr 2010 Actual patient number (429) added as reported by ClinicalTrials.gov.
- 04 Jan 2008 Status changed from recruiting to completed.